Claudio Pulito

National Cancer Institute — Malaysia

Medicine · Health Sciences

26h-index2.0kcitations90works2.82yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lung Cancer Treatments and Mutations(19), Cancer Genomics and Diagnostics(19), Cancer-related molecular mechanisms research(13), MicroRNA in disease regulation(11), Circular RNAs in diseases(10)

Publications90 total

Dissecting endometrial cancer complexity in response to standard and targeted therapies
Cell Death and Disease·2025Open Access
Circulating miR-18b-3p is a novel biomarker predicting chemo-radiotherapy induced oral mucositis in head and neck cancer
Signal Transduction and Targeted Therapy·2025Open Access
Dissecting endometrial cancer complexity in response to standard and targeted therapies
2025Open Access
6P Organoid models reveal endometrial cancer microenvironment and drug resistance
ESMO Open·2025Open Access
MicroRNA-mediated PTEN downregulation as a novel non-genetic mechanism of acquired resistance to PI3Kα inhibitors of head & neck squamous cell carcinoma
Drug Resistance Updates·2025· 2 citedOpen Access
CircPVT1 weakens miR-33a-5p unleashing the c-MYC/GLS1 metabolic axis in breast cancer
Journal of Experimental & Clinical Cancer Research·2025· 11 citedOpen Access
The oncogenic axis YAP/MYC/EZH2 impairs PTEN tumor suppression activity enhancing lung tumorigenicity
Cell Death Discovery·2024· 8 citedOpen Access
The oncogenic axis YAP/MYC/EZH2 impairs PTEN tumor suppression activity enhancing lung tumorigenicity
2024Open Access
Targeting of mutant-p53 and MYC as a novel strategy to inhibit oncogenic SPAG5 activity in triple negative breast cancer
Cell Death and Disease·2024· 7 citedOpen Access
CircPVT1 sponges miR-33a-5p unleashing the c-MYC/GLS1 metabolic axis in breast cancer
2024Open Access
MP65-20 BLADDER CANCER PATIENT-DERIVED ORGANOIDS: A NEW FRONTIER FOR PERSONALIZED THERAPY
The Journal of Urology·2024
Targeting of Mutant-p53 and MYC as a novel strategy to inhibit oncogenic SPAG5 activity in triple negative breast cancer
2024Open Access
Author Correction: Metformin-induced ablation of microRNA 21-5p releases Sestrin-1 and CAB39L antitumoral activities
Cell Discovery·2024· 1 citedOpen Access
Bladder cancer patient-derived organoids: A new frontier for personalized therapy
European Urology·2024
ID4-dependent secretion of VEGFA enhances the invasion capability of breast cancer cells and activates YAP/TAZ via integrin β3-VEGFR2 interaction
Cell Death and Disease·2024· 13 citedOpen Access
Immunosignatures associated with TP53 status and co-mutations classify prognostically head and neck cancer patients
Molecular Cancer·2023· 13 citedOpen Access
DARPP-32 and t-DARPP in the development of resistance to anti-HER2 agents. Pre-clinical evidence from the STEP study
Neoplasia·2023· 1 citedOpen Access
Exploiting Long Non-Coding RNAs and Circular RNAs as Pharmacological Targets in Triple-Negative Breast Cancer Treatment
Cancers·2023· 11 citedOpen Access
HSF-1/miR-145-5p transcriptional axis enhances hyperthermic intraperitoneal chemotherapy efficacy on peritoneal ovarian carcinosis
Cell Death and Disease·2023· 4 citedOpen Access
The new world of RNA diagnostics and therapeutics
Journal of Experimental & Clinical Cancer Research·2023· 5 citedOpen Access
page 1 of 5Next →

Frequent Co-authors

Giovanni Blandino(48), Sabrina Strano(41), Andrea Sacconi(37), Paola Muti(29), Sara Donzelli(18), Frauke Goeman(11), Federica Mori(9), Aldo Morrone(8), Mario Cioce(8), Raul Pellini(8), Federica Ganci(7), Etleva Korita(7), Giulia Fontemaggi(7), Alina Catalina Palcau(7), Valeria Canu(7), Gennaro Ciliberto(7), Giuseppe Sanguineti(6), Federica Lo Sardo(6), Maria Ferraiuolo(6), Maurizio Fanciulli(6)